Welcome to our dedicated page for GeoVax Labs Warrants news (Ticker: GOVXW), a resource for investors and traders seeking the latest updates and insights on GeoVax Labs Warrants stock.
GeoVax Labs, Inc. (OTCQB: GOVX) is a clinical-stage biotechnology company specializing in developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers.
Utilizing novel proprietary platforms like the modified vaccinia ankara - virus-like particle (MVA-VLP) vaccine platform, GeoVax's pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and gene-directed therapy for head and neck cancers.
Additional research programs focus on preventive vaccines against infectious diseases like Monkeypox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, along with immunotherapies for various solid tumors.
Recent achievements include positive initial safety and immune response findings from a Phase 2 clinical trial evaluating GEO-CM04S1, the COVID-19 vaccine, as a heterologous booster in 63 healthy adults who previously received the Pfizer or Moderna mRNA vaccine. The trial has demonstrated statistically significant increases in neutralizing antibody responses against multiple SARS-CoV-2 variants.
GeoVax Labs, Inc. (Nasdaq: GOVX) announced that Dr. Mark J. Newman will participate in the World Vaccine Congress Europe from October 19-21 in Barcelona. The discussion will focus on the development of universal/pan coronavirus vaccines. GeoVax is advancing its vaccine candidate, GEO-CM02, which targets multiple coronavirus proteins to enhance immunity and combat emerging variants. This first-generation vaccine aims to produce virus-like particles to stimulate both antibody and T-cell responses, thus broadening vaccine efficacy against circulating coronaviruses.
GeoVax Labs announced that its vaccine candidate, GEO-EM01, achieved 100% protection in rhesus macaques against a lethal dose of Ebola virus after a single dose. This marks a breakthrough as it’s the first report of such efficacy from a replication-deficient MVA vector. The U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent related to this vaccine. GeoVax is also advancing vaccines for other hemorrhagic fever viruses. The company holds over 70 pending or granted patent applications, reflecting its innovation portfolio.
GeoVax Labs has entered an exclusive license agreement with PNP Therapeutics for Gedeptin®, aimed at treating advanced head and neck cancers. The deal grants GeoVax rights to key intellectual property and clinical materials. Gedeptin has shown promise in early trials, demonstrating safety and tumor reduction in patients with solid tumors. The ongoing Phase 1/2 trial for recurrent head and neck squamous cell carcinoma is funded by the FDA, which has also granted Gedeptin orphan drug status, providing regulatory incentives.
GeoVax Labs, Inc. (Nasdaq: GOVX) announced that Chairman & CEO David Dodd will present at the H.C. Wainwright 23rd Annual Global Investment Conference, occurring virtually from September 13-15, 2021. Mr. Dodd’s presentation will be available for on-demand listening starting at 7:00 AM ET on September 13, 2021. The conference will allow participants to register and view the presentation online. GeoVax is a biotechnology firm dedicated to developing vaccines for infectious diseases and cancer, utilizing a unique MVA-VLP based platform to stimulate robust immune responses.
GeoVax Labs, Inc. (Nasdaq: GOVX) presented data at the ESMED General Assembly regarding their COVID-19 vaccine candidate, GEO-CM02, which aims to provide broader immunity against evolving SARS-CoV-2 variants. Utilizing the GV-MVA-VLP™ platform, the vaccine targets multiple proteins to potentially reduce immune escape risks. Dr. Mark J. Newman highlighted positive efficacy results from animal studies, indicating that the vaccine induces functional antibodies and T-cell responses. GeoVax envisions its vaccine as a key component in future coronavirus vaccination strategies.
GeoVax Labs, Inc. (Nasdaq: GOVX) announced its participation in the SNN Network Summer Virtual Event 2021 on August 18, 2021, at 12:30 PM EST. CEO David Dodd will present and address investor queries during the session. The event offers a chance for one-on-one meetings with the company through secure video conferencing. GeoVax specializes in developing vaccines against infectious diseases and cancers, using a unique MVA-VLP based platform. The company is focused on ongoing vaccine programs for COVID-19, HIV, and other critical diseases.
GeoVax Labs, Inc. (GOVX) announced its Q2 2021 financial results, reporting a net loss of $1,314,033 ($0.21 per share), compared to a loss of $455,204 ($0.66 per share) in Q2 2020. The increase in losses is attributed to higher R&D and administrative expenses, particularly related to their COVID-19 vaccine program. As of June 30, 2021, cash balances increased to $19.5 million, bolstered by stock sales and warrant exercises. The company continues to advance its COVID-19 vaccine and cancer immunotherapy programs, supported by an SBIR grant and collaborations.
GeoVax Labs, Inc. (GOVX) will report its second quarter 2021 financial results on August 11, 2021, after market close. A conference call is scheduled for the same day at 4:30 p.m. ET, where management will review financial results and corporate updates. Participants can pre-register for the call and will receive dial-in details. GeoVax is focused on developing vaccines against infectious diseases and cancer using its patented MVA-VLP platform, with ongoing programs for COVID-19, HIV, and more.
GeoVax Labs announced a significant breakthrough in vaccine development with its MVA-SUDV-VLP vaccine, achieving 100% protection against the Sudan Ebolavirus (SUDV) in preclinical studies. This innovative vaccine, which only requires a single dose, was presented at the American Society for Virology's annual meeting. The vaccine’s efficacy was demonstrated in guinea pigs, showing that it can protect against a lethal challenge of SUDV. GeoVax aims to advance this vaccine to non-human primate testing, further establishing its platform's ability to combat infectious diseases.
GeoVax Labs (Nasdaq: GOVX) announced the issuance of U.S. Patent No. 11,052,148 for a vaccine targeting the Hepatitis B virus, addressing an unmet therapeutic need for over 250 million people globally. This patent supports a modified vaccinia Ankara (MVA) vector designed to generate an immune response, applicable for both prevention and treatment of chronic HBV infections. The patent arises from a collaboration with Georgia State University. The company focuses on developing human immunotherapies and vaccines for infectious diseases and cancer.
FAQ
What is the current stock price of GeoVax Labs Warrants (GOVXW)?
What is GeoVax Labs, Inc. focused on developing?
What recent achievements has GeoVax Labs, Inc. made?
Which diseases are targeted by GeoVax's vaccine development programs?
